US Patent 8,822,481: Ruxolitinib Phosphate Claims, Scope, Expiration, and Patent Landscape
US Patent 8,822,481 protects methods of administering crystalline ruxolitinib phosphate, including the 1:1 phosphate salt, to inhibit or modulate JAK1 and JAK2. The patent is a method-of-treatment patent, not a basic compound patent. Its commercial relevance is tied primarily to Jakafi tablets and the ruxolitinib phosphate active pharmaceutical ingredient. The claims do not recite a specific disease, dosage, strength, route, or treatment regimen, which gives the patent broad claim language but leaves important infringement and validity questions around claim construction, enablement, written description, and proof of JAK1/JAK2 inhibition.
The patent does not cover every ruxolitinib product. Its strongest application is against an oral product that administers the claimed ruxolitinib phosphate salt, particularly the claimed crystalline 1:1 salt. It is less directly applicable to products using ruxolitinib free base, different salts, non-crystalline material, or a different dosage form unless those products fall within the patent's claim construction.
What compound does US Patent 8,822,481 protect?
US 8,822,481 covers the phosphate salt of ruxolitinib, also known as INCB018424. The claimed chemical entity is:
(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt.
Ruxolitinib is a small-molecule Janus kinase inhibitor. The relevant pharmacology is inhibition of JAK1 and JAK2 signaling. The phosphate salt is the active ingredient used in Jakafi tablets and Jakavi tablets.
| Item |
Analysis |
| Active ingredient |
Ruxolitinib |
| Salt |
Ruxolitinib phosphate |
| Stereochemistry |
R configuration |
| Target |
JAK1 and/or JAK2 |
| Product most closely implicated |
Jakafi tablets |
| Patent type |
Method of treatment and pharmaceutical-composition method claims |
| Patent number |
US 8,822,481 |
| Issue date |
September 2, 2014 |
| Applicant/owner associated with estate |
Incyte Corporation and affiliated Incyte entities |
| Core commercial market |
Myelofibrosis, polycythemia vera, and graft-versus-host disease |
What are the independent claims in US 8,822,481?
The patent has four principal independent claims.
Claims 1 and 15 cover administering ruxolitinib phosphate to a patient to inhibit or modulate JAK1 and/or JAK2.
Claims 8 and 22 cover administering a pharmaceutical composition containing ruxolitinib phosphate and a pharmaceutically acceptable carrier to achieve the same JAK1/JAK2 inhibition or modulation.
The independent claims can be summarized as follows:
| Claim group |
Required elements |
Commercial effect |
| Claims 1-7 |
Administration of ruxolitinib phosphate; dependent claims narrow to JAK1, JAK2, crystalline salt, and 1:1 salt |
Direct method claim focused on the active salt |
| Claims 8-14 |
Administration of a composition containing ruxolitinib phosphate and a carrier |
Adds formulation language but does not require a particular tablet composition |
| Claims 15-21 |
Administration to modulate JAK1/JAK2 activity |
Broad functional method language |
| Claims 22-28 |
Administration of a pharmaceutical composition to modulate JAK1/JAK2 |
Composition-based version of claims 15-21 |
The dependent claims create two important narrowing limitations:
- The ruxolitinib phosphate is crystalline.
- The crystalline salt is a 1:1 ruxolitinib-to-phosphoric-acid salt.
The patent therefore has a broad tier and a narrower solid-state tier. A defendant may challenge whether a particular product contains the claimed phosphate salt, whether the material is crystalline, and whether the salt stoichiometry is 1:1.
How broad are the claims to ruxolitinib phosphate?
The claims are broad in therapeutic function and relatively specific in chemical identity.
Broad elements
The claims do not limit:
- The disease being treated
- The patient age
- The dose
- The dosing frequency
- The route of administration
- The treatment duration
- The JAK1-to-JAK2 selectivity ratio
- The dosage form
- The specific pharmaceutical carrier
- Whether JAK1, JAK2, or both are inhibited, where the independent claim uses “and/or”
This breadth allows the patent to reach uses beyond the original commercial indications if the accused product administers the claimed salt and the treatment produces the claimed JAK1/JAK2 activity.
Narrow elements
The claims require:
- The R enantiomer of the ruxolitinib molecule
- The phosphoric acid salt
- Administration to a patient
- An effective amount
- Inhibition or modulation of JAK1 and/or JAK2
Claims 4-7, 11-14, 18-21, and 25-28 add crystallinity and, in the narrowest claims, 1:1 stoichiometry.
The patent does not claim the ruxolitinib free base as such. It also does not claim all ruxolitinib salts. A product using a different counterion may present a non-infringement position, although doctrine-of-equivalents arguments could become relevant depending on the product and litigation record.
What is the scope of the crystalline-salt claims?
The crystalline-salt claims are the most product-specific portion of US 8,822,481. They are directed to treatment methods using crystalline ruxolitinib phosphate, with the narrowest claims requiring a 1:1 molar ratio between ruxolitinib and phosphoric acid.
The claims do not appear, from the supplied claim text, to require a particular X-ray powder diffraction pattern, melting point, hydration state, polymorph designation, particle size, or manufacturing process. That distinction matters. A claim requiring only “crystalline” material may be broader than a claim limited to a specific polymorph, but it may also face greater validity scrutiny if the specification does not adequately distinguish the claimed solid form from known or predictable forms.
For generic litigation, the relevant technical evidence would typically include:
- Salt identity
- Counterion confirmation
- Molar stoichiometry
- Crystallinity
- Polymorphic form
- Hydration or solvation state
- Batch-to-batch solid-state consistency
- Drug product composition
- ANDA labeling and proposed use
What does US 8,822,481 not cover?
US 8,822,481 does not, based on the supplied claims, expressly claim:
- Ruxolitinib free base
- A different ruxolitinib salt
- A specific tablet formulation
- A particular excipient system
- A manufacturing process
- A specific polymorph defined by analytical parameters
- A topical cream formulation
- A specific disease such as myelofibrosis or graft-versus-host disease
- A method limited to a defined dosage or dosing schedule
- A combination treatment with another active ingredient
This distinction is important for the relationship between Jakafi and Opzelura. Jakafi is an oral ruxolitinib phosphate product. Opzelura is a topical ruxolitinib product and is supported by a separate patent and regulatory estate. US 8,822,481 should not be treated as a universal ruxolitinib patent covering all dosage forms.
When does US Patent 8,822,481 lose exclusivity?
The underlying priority and patent-term records must be read together with the USPTO patent file and FDA Orange Book. Public patent records associate US 8,822,481 with a 2009 priority period and a nominal term extending into 2029. The patent may also be affected by patent-term adjustment, terminal-disclaimer treatment, pediatric extension, or Orange Book listing conventions.
For commercial analysis, the relevant date is the FDA-recognized expiration date for the listed Jakafi patent, not simply the 20-year calculation from the earliest priority filing. The US Orange Book should be used as the controlling commercial reference for any ANDA launch analysis. FDA, Approved Drug Products with Therapeutic Equivalence Evaluations.
| Exclusivity category |
Relevance to US 8,822,481 |
| Patent term |
Extends into the late 2020s based on public family and Orange Book records |
| New chemical entity exclusivity |
Expired; Jakafi was approved in 2011 |
| Orphan-drug exclusivity |
Applied to certain indications and periods, but does not replace the patent analysis |
| Pediatric exclusivity |
May add six months to qualifying listed exclusivity, if applicable |
| Regulatory exclusivity today |
Patent protection is more important than original regulatory exclusivity |
| Generic launch date |
Depends on ANDA approval, Paragraph IV litigation, settlement terms, and the enforceable patent term |
What is the Orange Book status of ruxolitinib and Jakafi?
Jakafi was approved by the FDA in 2011 for intermediate- or high-risk myelofibrosis. FDA later approved ruxolitinib for polycythemia vera and acute and chronic graft-versus-host disease. The oral product is listed under ruxolitinib phosphate.
The Orange Book analysis should separate:
- Drug-substance or active-ingredient patents.
- Method-of-use patents.
- Formulation or solid-state patents.
- Regulatory exclusivity.
- Any patents listed for particular approved indications.
US 8,822,481 is commercially significant because its claims are directed to administering the phosphate salt for JAK1/JAK2 inhibition. Even without a disease limitation, an ANDA applicant proposing the same active salt for an FDA-approved use may face a Paragraph IV certification and infringement action.
A key limitation is that Orange Book listing does not establish validity or infringement. Listing identifies patents that the NDA holder asserts claim the drug, formulation, or approved method of use. The patent holder still must prove infringement and defend validity in district court.
Which patents are relevant to the ruxolitinib patent estate?
The principal US estate includes the following categories:
| Patent category |
Representative asset |
Strategic role |
| Basic compound patent |
US 7,598,257 |
Covers ruxolitinib-type chemical matter and is central to the original product estate |
| Salt and treatment patent |
US 8,822,481 |
Covers administration of ruxolitinib phosphate for JAK1/JAK2 inhibition |
| Solid-state and formulation rights |
Related family members and later filings |
May protect crystalline forms, formulations, or manufacturing attributes |
| Method-of-use patents |
Later Jakafi indication patents |
Can delay an unrestricted generic launch for listed indications |
| Topical product patents |
Separate ruxolitinib cream estate |
Relevant to Opzelura, not automatically to Jakafi tablets |
The value of US 8,822,481 depends on how many additional patents remain enforceable against the same ANDA. A generic applicant may avoid one method-of-use patent through a section viii “skinny label,” but that strategy becomes harder where the patent claims the administration of the active salt without a disease limitation or where all commercially important uses remain covered by listed claims.
Are there Paragraph IV challenges to US 8,822,481?
A Paragraph IV certification would assert that the listed patent is invalid, unenforceable, or not infringed. For ruxolitinib, the commercial risk is determined by the full Orange Book portfolio rather than US 8,822,481 in isolation.
The main possible Paragraph IV theories would include:
- The proposed generic does not contain the claimed phosphate salt.
- The proposed product does not contain crystalline material.
- The salt is not a 1:1 salt.
- The ANDA label does not induce the claimed JAK1/JAK2 method.
- The claims lack written description or enablement.
- The claims are anticipated or obvious based on earlier ruxolitinib disclosures.
- The patent is unenforceable because of inequitable conduct or other litigation-specific grounds.
- The asserted claims are invalid under patent-eligibility or indefiniteness theories.
A Paragraph IV notice generally triggers a 45-day period for the NDA holder to file suit. A timely suit can create a 30-month stay of FDA approval under the Hatch-Waxman framework, subject to statutory exceptions and court action. The existence of a Paragraph IV certification does not itself establish a generic launch date.
How strong is the patent estate for ruxolitinib?
The estate has meaningful commercial strength because it combines:
- A commercially validated JAK1/JAK2 inhibitor.
- A defined R enantiomer.
- A marketed phosphate salt.
- Broad treatment language.
- Crystalline and 1:1 salt limitations.
- Multiple approved indications.
- A separate product estate for topical ruxolitinib.
US 8,822,481 is strongest when an accused product uses the same ruxolitinib phosphate salt and is labeled for JAK1/JAK2-mediated indications. It is weaker where the accused product uses another salt, free base, or a formulation whose label omits the claimed use.
Validity risk is concentrated in the breadth of the functional method claims. The chemical identity is specific, but the therapeutic language is expansive. The narrower crystalline and 1:1 claims may provide stronger product linkage but can create technical disputes over solid-state characterization and the disclosure supporting the claimed scope.
What generic entry risks exist for Jakafi?
A generic launch could occur through several pathways:
| Launch pathway |
Risk to innovator |
| Litigation victory for ANDA applicant |
Potential early launch before the last listed patent expiration |
| Settlement with licensed entry |
Controlled erosion on an agreed date |
| Skinny-label launch |
Entry for non-patented indications while excluding protected uses |
| At-risk launch |
Immediate exposure to damages, injunction, and market disruption |
| Post-expiration launch |
Broad substitution and rapid price erosion |
Because ruxolitinib is a small molecule, biosimilar rules do not apply. Generic applicants use the ANDA pathway, not the biosimilar pathway under section 351(k) of the Public Health Service Act.
What licensing deals affect ruxolitinib?
Incyte retained US commercial control of Jakafi. Novartis commercialized Jakavi in markets outside the United States under a collaboration arrangement with Incyte. The geographic division is important because US patent analysis does not determine European, Canadian, Japanese, or other national launch rights.
| Region |
Primary commercial structure |
| United States |
Incyte, Jakafi |
| Many ex-US markets |
Novartis, Jakavi, under collaboration rights |
| Topical ruxolitinib |
Incyte, Opzelura in relevant markets |
Patent rights, regulatory approvals, and licensing arrangements must be assessed country by country. A US method patent has no direct blocking effect on an ex-US launch.
What manufacturing and IP barriers remain?
Manufacturing barriers are secondary to the patent claims but still commercially relevant. A generic manufacturer must reproduce a pharmaceutically acceptable ruxolitinib product with suitable control of:
- Enantiomeric purity
- Salt formation
- Crystalline state
- Particle characteristics
- Stability
- Dissolution
- Tablet performance
- Impurity profile
- Scale-up consistency
The phosphate salt and crystalline form may create process-development constraints even if a generic ultimately succeeds in avoiding the patent claims. A process that produces the same crystalline 1:1 salt can increase infringement exposure under the treatment claims, although the patent does not appear from the supplied claims to contain a standalone process claim.
Key Takeaways
- US 8,822,481 covers methods of administering ruxolitinib phosphate to inhibit or modulate JAK1 and/or JAK2.
- The patent is directed to a salt and treatment method, not the broad ruxolitinib molecule alone.
- The narrowest claims require crystalline 1:1 ruxolitinib phosphate.
- The claims do not recite a disease, dosage, route, tablet strength, or dosing schedule.
- Jakafi tablets are the principal commercial product implicated.
- Opzelura and other non-oral ruxolitinib products require separate patent analysis.
- Generic applicants face ANDA and Paragraph IV risks, not biosimilar litigation.
- The enforceable expiration date should be taken from the current FDA Orange Book and USPTO patent records, including any terminal disclaimer, patent-term adjustment, or pediatric extension.
- The strongest infringement case involves a generic product that contains crystalline ruxolitinib phosphate and is labeled for an indication requiring JAK1/JAK2 inhibition.
- The main design-around opportunities involve free base, a different salt, a different crystalline form, or a label that omits the claimed use.
FAQs About US Patent 8,822,481 and Ruxolitinib
Does US 8,822,481 cover ruxolitinib free base?
The supplied claims identify ruxolitinib phosphoric acid salt. They do not expressly claim ruxolitinib free base.
Does the patent cover all ruxolitinib salts?
No. The claims specifically identify the phosphoric acid salt. A different salt would require a separate infringement and equivalents analysis.
Does US 8,822,481 cover Opzelura cream?
Not automatically. Opzelura is a topical ruxolitinib product with a separate formulation and patent estate. The oral ruxolitinib phosphate claims should not be assumed to cover the cream.
Can a generic launch with a skinny label avoid this patent?
Possibly, but the result depends on the approved uses, the proposed labeling, the patent listing, and whether the remaining label still induces infringement of the claimed JAK1/JAK2 method.
Is ruxolitinib a biologic requiring a biosimilar application?
No. Ruxolitinib is a small molecule. A generic applicant would ordinarily use the ANDA pathway under the Hatch-Waxman Act.
References
-
U.S. Food and Drug Administration. (2011). FDA approves Jakafi to treat myelofibrosis. FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
-
U.S. Patent No. 7,598,257. (2009). Inhibitors of Janus kinase 1 and Janus kinase 2. United States Patent and Trademark Office.
-
U.S. Patent No. 8,822,481. (2014). Methods of treating with a JAK inhibitor. United States Patent and Trademark Office.
-
Incyte Corporation. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission.
-
Novartis Pharmaceuticals Corporation and Incyte Corporation. (2014). Collaboration agreement for ruxolitinib outside the United States. Company announcement.
